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Abstract
Background & Aims: The long-term clinical outcomes in initial survivors
with acute liver failure (ALF) are not well known. The aim of this study was
to provide an overview of the 2-year clinical outcomes among initial survi-
vors and liver transplant (LT) recipients that were alive 3 weeks after enrol-
ment in the Acute Liver Failure Study Group (ALFSG). Methods: Outcomes
in adult ALFSG patients that were enrolled between 1998 and 2010 were
reviewed. Results: Two-year patient survival was significantly higher in the
262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP)
spontaneous survivors (SS) (89.5%) and 200 non-APAP SS (75.5%)
(P < 0.0001). The causes of death were similar in the three groups but the
time to death was significantly longer in the LT recipients (P < 0.0001).
Independent predictors of 2-year mortality in the APAP group were a high
serum phosphate level and patient age (c-statistic = 0.65 (0.54, 0.76)),
patient age and days from jaundice to ALF onset in the non-APAP group (c-
statistic = 0.69 (0.60, 0.78)), and patient age, days from jaundice, and higher
coma grade in the LT recipients (c-statistic = 0.74 (0.61, 0.87)). The LT
recipients were significantly more likely to be employed and have a higher
educational level (P < 0.05). Conclusions: Two-year outcomes in initial sur-
vivors of ALF are generally good but non-APAP patients have a significantly
lower survival which may relate to pre-existing medical comorbidities. Spon-
taneous survivors with APAP overdose experience substantial morbidity dur-
ing follow-up from ongoing psychiatric and substance abuse issues.
Acute liver failure (ALF) is a rare but dramatic illness
associated with a high rate of short-term morbidity and
mortality (1, 2). The likelihood of an early adverse out-
come including the need for emergency liver transplan-
tation (LT) is, in part, related to the aetiology of ALF,
peak grade of encephalopathy and development of
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multi-organ failure (1–4). Results of several studies have
demonstrated a lower 1-year patient survival in ALF LT
recipients compared to those with cirrhosis undergoing
LT because of the emergency nature of the surgery, cere-
bral oedema, and frequent need for life support in the
ALF patients (2, 3). In addition, a higher rate of allograft
dysfunction including acute and chronic rejection, de
novo autoimmune hepatitis, and recurrent graft failure
have been demonstrated during follow-up in ALF LT
recipients (5–7). Furthermore, variable degrees of neu-
rological sequelae in long-term survivors of ALF have
been reported but the number of patients evaluated has
been small (8, 9).
The USA Acute Liver Failure Study Group (AL-
FSG) is a consortium of 13 academic medical centres
that is conducting an ongoing observational registry
study of adult ALF patients (2). Important insights
into the aetiology, disease-specific prognosis and clini-
cal correlates of early adverse outcomes have been
reported (1, 2). In addition to collecting detailed clin-
ical, demographical, and outcome data up to 3 weeks
after enrolment, this study includes a prospective
assessment of patient outcomes at 1 and 2 years after
enrolment. This effort has proven useful in better
defining the long-term clinical outcomes in specific
subgroups of ALF patients (10, 11). The aim of this
study was to provide an overview on the 2-year clini-
cal outcomes among initial survivors and LT recipi-
ents who were alive 3 weeks after enrolment in the
ALFSG. Baseline demographics and clinical factors
associated with impaired long-term survival were
identified as well as the frequency of various clinical
complications among the following three groups: acet-
aminophen (APAP) initial spontaneous survivors (SS),
non-APAP initial SS, and LT recipients. We hypothe-
sized that LT recipients would have poorer long-term
outcomes because of their more severe illness necessi-
tating emergency surgery. Multivariate models to
identify patients at risk of dying within 2 years of fol-
low-up were constructed to provide prognostic data
for clinicians.
Patients and methods
Patient selection
The ALFSG database consists of 1850 adult patients
with ALF admitted to one of 13 actively or 10 previ-
ously enrolling clinical sites from 1 January 1998 to 1
July 2010. Eligible ALF patients had symptoms of
jaundice or illness of <26 weeks prior to admission
and mental status changes with coagulopathy defined
as an international normalized ratio (INR) >1.5 with-
out known underlying chronic liver disease. The pro-
tocol was reviewed and approved by the Institutional
Review Board at all of the participating sites and
written informed consent was obtained from the
patient’s next of kin. In addition to baseline
demographics and presenting features, detailed infor-
mation during the first 7 days of enrolment including
imaging, lab, and clinical data, as well as short-term
outcome data were obtained through 21 days after
admission.
Long-term follow-up protocol and data collection
In calendar year 2000, the ALFSG observational study
was amended to include a 12-month study visit to be
performed at 6–18 months after enrolment as well as a
24-month study visit completed any time after
18 months from enrolment. Data obtained at these vis-
its included incremental medical history, medications,
liver biopsy and imaging data, and laboratory variables.
In addition, various complications were prospectively
tracked including neurological complications. Data were
collected at a face to face study visit or via telephone
interview and/or chart review. For patients that were
lost to follow-up, sites queried the Social Security death
index database and reviewed medical records. To be
included in the analysis population, patients must have
survived to short-term follow-up at 21 days (1138
patients) and either have a recorded death or at least
one long-term follow-up form completed 21 days after
enrolment (773 patients). For the current analysis,
patients were stratified on whether they received a liver
transplant (LT), and the 3-week initial spontaneous sur-
vivors were further stratified by presence of APAP-
related or other non-APAP aetiology.
Statistical analysis
SAS software version 9.2 (SAS Institute Inc. Cary, NC,
USA) was used to perform statistical analysis. Baseline
variables were described using counts and percentages
for categorical data, or mean and standard deviations
(medians and interquartile ranges) for continuous nor-
mal (skewed) data. For variables identified as clinically
relevant, statistical tests were performed using chi-
square, ANOVA, or Kruskal–Wallis tests. Owing to the
low event rate in each of the populations, 2-year mortal-
ity was reported using cumulative per cent and tested
using a test of independent proportions. Predictors of
death were modelled with univariate and multivariate
logistic regression, with predictors identified using step-
wise elimination based on significance and overall good-
ness of fit. Variables with a P < 0.20 on univariate
analyses were considered for the multivariable analysis.
Results of the modelling are expressed as odds ratios
with 95% confidence intervals. The c-statistic and corre-
sponding 95% confidence interval are based on an
approximation (12).
Results
There were 1138 adult ALF patients alive at 3 weeks
after initial enrolment into the ALFSG registry between
Liver International (2015)
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January 1998 and July 2010 (Fig. 1). Long-term follow-
up data were available in 773 (68%) of these patients.
Among the 773 patients included in this analysis, there
were 262 LT recipients and 511 initial spontaneous sur-
vivors (SS) which included 306 with APAP overdose
and 200 with ALF because of other non-APAP aetiolo-
gies (Table 1). The patients not included in this analysis
were similar in baseline demographical and clinical fea-
tures except that the excluded population was more
likely to have experienced APAP overdose (Table S1).
The 306 patients in the APAP initial SS group were
younger and significantly more likely to be female, Cau-
casian, and of non-Hispanic ethnicity compared to the
other two patient groups. As expected, the APAP initial
survivors had the shortest duration of symptoms, the
highest serum aminotransferase levels and lowest biliru-
bin levels at presentation. The APAP initial survivors
were also significantly more likely to have active psychi-
atric and substance abuse comorbidities at enrolment
and a positive urine toxicology screen. A careful review
of the cases demonstrated that 116 of these were inten-
tional APAP overdose patients and 159 were non-inten-
tional therapeutic misadventures, while 31 were of
unknown intent. The majority of LT recipients were also
women and they had a significantly longer duration of
symptoms to jaundice, higher total bilirubin and lower
serum aminotransferase levels at presentation compared
to the other two groups. The frequency of observed aeti-
ologies of ALF in the LT recipients differed when com-
pared to non-APAP initial SS (P ≤ 0.001). The LT
recipients also had the highest INR, lactate, and model
for end-stage liver disease (MELD) scores at presenta-
tion. Although the level of hepatic encephalopathy was
similar in all three patient groups at admission, the LT
recipients were more likely to have an intracranial
pressure (ICP) monitor placed, require mechanical
intubation, and receive pressors and mannitol during
their illness compared to the other two patient groups.
Two-year patient survival
The 2-year actuarial patient survival was highest in the
LT recipients (92.4%) followed by the APAP initial SS
(89.5%) and non-APAP initial SS (75.5%). Cumulative
death rates are presented in Fig. 2. The median time to
death in the LT recipients of 223 days (range: 23–
568 days) was significantly longer compared to the
other two patient groups (P < 0.001). Overall, the lead-
ing causes of death were liver related (17%), infection/
sepsis (12%), and multisystem organ failure (18%), but
45% of the deaths were of unknown cause (Table 2).
The identified causes of death were similar in the three
patients groups.
Predictors of impaired long-term survival
Multivariate models were constructed to identify base-
line variables associated with impaired 2-year survival in
each of the three patient groups (Table 3). Univariate
analyses of the admission clinical data were used to
identify potential variables for model building.
Acetaminophen initial spontaneous survivors
Older patient age, serum alanine aminotransferase
(ALT) as well as elevated serum phosphate, lower arte-
rial pH, and higher initial coma grade were significant
predictors of death on univariate analysis. In the multi-
variate model, age and phosphate remained as consis-
tent predictors of death with an elevated phosphate level
indicating higher risk of death (OR: 1.26, 95% CI: 1.05,
1.51). The median age of the APAP patients that died
during follow-up was 42, while the median age of the
long-term survivors was 35. The median admission
phosphate of those that died was 2.75 mg/dl compared
to 2.20 mg/dl in those that survived. Of note, the
proportion of patients with intentional APAP overdose
was similar in the long-term survivors and non-survi-
vors (41% vs. 42%, P = 0.93) as was the presence of
psychiatric comorbidities (44% vs. 56%, P = 0.19).
Non-acetaminophen spontaneous survivor group
Older patient age, non-Hispanic ethnicity, <12 years of
education, increased days of jaundice to ALF, serum
ALT, higher INR and pressor use were examined as
potential predictors of death for the multivariate analy-
sis. Of note, initial coma grade, need for dialysis and
intubation were not associated with long-term survival
in univariate analyses. In the multivariate model, age
and days from jaundice to ALF were the only indepen-
dent predictors of death in this patient group. The med-
ian age of the non-APAP patients who died was 50 vs.
42 in those that survived. The aetiologies of ALF in
Fig. 1. ALF patients included in the current analysis. Among the
773 ALF patients eligible for this study, there were 262 liver trans-
plant (LT) recipients and 511 initial spontaneous survivors (SS) who
were alive 3 weeks after enrolment into the ALFSG registry.
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Table 1. Baseline characteristics of the long-term follow-up ALF patient groups
N
APAP
initial
survivors
(N = 306)
Non-APAP
initial
survivors
(N = 200)
LT recipient
(N = 262) P-value
Demographics
Age (years) 768 37.5 ± 12.5 42.6 ± 15.2 38.9 ± 13.7 <0.001
% Female 768 235 (76.8) 122 (61.0) 167 (63.7) <0.001
Race
% Caucasian 768 266 (86.9) 138 (69.0) 183 (69.8) <0.001
% Black 23 (7.5) 41 (20.5) 46 (17.6)
% Other 17 (5.6) 21 (10.5) 33 (12.6)
Ethnicity (% Not Hispanic/Latino) 768 293 (95.8) 182 (91.0) 231 (88.2) 0.004
Marital status
% Married 495 78 (39.6) 58 (52.3) 108 (57.8) 0.01
% Never married 79 (40.1) 37 (33.3) 54 (28.9)
% Other 40 (20.3) 16 (14.4) 25 (13.4)
Employment
% Employed 768 67 (21.9) 50 (25.0) 114 (43.5) <0.001
% Other 44 (14.4) 33 (16.5) 43 (16.4)
% Unknown 195 (63.7) 117 (58.5) 105 (40.1)
Years of education 474 12.5 ± 2.4 12.9 ± 2.6 13.5 ± 2.6 0.001
Medical history
Aetiology
% APAP 764 306 (100.0) 0 (0.0) 33 (12.8) <0.001*
% Autoimmune hepatitis 0 (0.0) 21 (10.5) 37 (14.3)
% DILI 0 (0.0) 48 (24.0) 55 (21.3)
% Hepatitis A 0 (0.0) 13 (6.5) 7 (2.7)
% Hepatitis B 0 (0.0) 22 (11.0) 32 (12.4)
% Shock/Ischaemia 0 (0.0) 38 (19.0) 1 (0.4)
% Indeterminate 0 (0.0) 33 (16.5) 68 (26.4)
% Other 0 (0.0) 25 (12.5) 25 (9.7)
Symptoms to ALF (days) 739 3.0 ± 2.0 10.0 ± 14.0 17.0 ± 23.2 <0.001
Jaundice to ALF (days) 635 1.0 ± 2.0 5.0 ± 8.5 11.5 ± 17.0 <0.001
Weight (kg) 728 72.5 ± 19.8 80.6 ± 21.3 80.2 ± 20.7 <0.001
% Psychiatric disease 768 167 (54.6) 54 (27.0) 34 (13.0) <0.001
% Substance abuse 768 140 (45.8) 29 (14.5) 21 (8.0) <0.001
% History of IDU 756 41 (13.6) 16 (8.1) 4 (1.6) <0.001
% Hypertension 768 32 (10.5) 53 (26.5) 34 (13.0) <0.001
% Endocrine/Diabetes 768 31 (10.1) 40 (20.0) 34 (13.0) 0.006
% Heart disease 768 14 (4.6) 25 (12.5) 11 (4.2) <0.001
Presenting labs
AST (IU/L) 765 2805 ± 6300 1048 ± 2070 626 ± 1431 <0.001
ALT (IU/L) 761 3272 ± 4226 1454 ± 2358 766 ± 1762 <0.001
INR 759 2.5 ± 2.0 2.1 ± 1.2 3.1 ± 2.3 <0.001
Bilirubin (mg/dl) 764 4.1 ± 3.6 9.9 ± 14.6 22.1 ± 16.3 <0.001
MELD 754 27.8 ± 8.9 29.3 ± 7.1 34.8 ± 7.4 <0.001
Phosphate (IU/L) 655 2.3 ± 1.8 3.3 ± 2.1 3.3 ± 2.1 <0.001
Creatinine (mg/dl) 767 1.4 ± 2.1 1.4 ± 1.9 1.1 ± 1.6 0.055
Lactate (mmol/L) 396 3.2 ± 3.6 3.5 ± 3.3 4.9 ± 6.7 <0.001
% Urine tox screen positive 768 180 (58.8) 48 (24.0) 48 (18.3) <0.001
Clinical complications at admission
% Pressors 748 32 (10.6) 29 (14.9) 37 (14.7) 0.259
% Intubated 766 130 (42.5) 72 (36.2) 95 (36.4) 0.228
% Grade ¾ HE 766 134 (43.8) 70 (35.2) 98 (37.5) 0.115
% Mannitol 759 29 (9.6) 13 (6.5) 37 (14.4) 0.02
% ICP monitor 705 21 (7.3) 11 (6.0) 31 (13.3) 0.015
% Dialysis/CVVH 753 63 (20.8) 28 (14.2) 51 (20.2) 0.150
Peak labs
ALT (IU/L) 768 3677 ± 4669 1479 ± 2391 939 ± 2071 <0.001
INR 763 2.8 ± 2.3 2.4 ± 1.1 3.8 ± 2.9 <0.001
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those who died varied, but there was no specific non-
APAP aetiology which was over-represented in those
who died vs. survived (Table S2a, P = 0.35). Of the 49
patients who died with non-APAP ALF, only five
(10.2%) were listed for liver transplant, while 32 of the
151 survivors (21.1%) were initially listed for LT during
their hospitalization.
Liver transplant recipients
In the multivariate model for LT recipients, age, days
from jaundice to ALF onset and higher coma grade
remained as consistent predictors of death with older
patient age indicating higher risk of death (10 years OR:
1.53, 95% CI: 1.06, 2.21). There did not appear to be an
over-representation of any particular aetiology of ALF
in those who died vs. survived (Table S2b, P = 0.07).
However, 12% of the APAP LT recipients died as well as
11% of the autoimmune patients and 5% of the drug-
induced liver injury (DILI) patients. Although the pro-
portion of patients with advanced encephalopathy
(Grade ¾) at presentation was significant on univariate
analysis, this did not persist in multivariate analysis. The
Table 2. Causes of death in ALF patients
APAP initial
survivors (N = 32)
Non-APAP initial
survivors (N = 49) LT recipients (N = 20)
% Liver related 9.4 18.4 25.0
% Infection/sepsis 12.5 12.2 10.0
% Cardiac 0.0 8.2 10.0
% Neurological 6.3 4.1 10.0
% Multisystem organ failure 28.1 8.2 25.0
% Other 12.5 6.1 15.0
% Unknown 40.6 53.1 30.0
Days to death
Median (IQR)*
57.0 (84.0) 57.0 (95.0) 222.5 (380.5)
*P < 0.001 Patients can have multiple causes of death.
Fig. 2. Actuarial 2-year mortality among the 773 initial 3-week sur-
vivors. The liver transplant recipients (C) had the highest 2-year sur-
vival (92.4%) compared to the acetaminophen overdose (A)
spontaneous survivors (89.5%) and the non-acetaminophen (B)
spontaneous survivors (75.0%) (P < 0.0001).
Table 1 (continued)
N
APAP
initial
survivors
(N = 306)
Non-APAP
initial
survivors
(N = 200)
LT recipient
(N = 262) P-value
Bilirubin (mg/dl) 768 7.0 ± 8.2 14.2 ± 16.4 24.8 ± 14.0 <0.001
MELD 763 29.6 ± 9.2 31.0 ± 7.2 37.1 ± 7.4 <0.001
Creatinine (mg/dl) 768 1.9 ± 3.9 1.7 ± 2.8 1.4 ± 2.1 0.041
Lactate (mmol/L) 449 3.3 ± 3.9 3.7 ± 3.6 4.9 ± 6.6 <0.001
Clinical complications during ALF hospitalization
% Pressors 768 57 (18.6) 38 (19.0) 71 (27.1) 0.029
% Intubated 768 160 (52.3) 85 (42.5) 159 (60.7) <0.001
% Grade ¾ HE 766 162 (52.9) 89 (44.7) 149 (57.1) 0.03
% Mannitol 768 51 (16.7) 19 (9.5) 58 (22.1) 0.001
% ICP monitor 768 36 (11.8) 13 (6.5) 60 (22.9) <0.001
% Dialysis/CVVH 768 99 (32.4) 52 (26.0) 86 (32.8) 0.222
*Compares the proportion of non-APAP aetiologies between the non-APAP SS and LT recipients.
DILI, drug-induced liver injury; IDU, intravenous drug use.
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median age of the LT recipients who died was 45.5 com-
pared to 38 years in those who survived. The median
days to jaundice of the LT recipients who died was 6
compared to 12 in those who survived. The proportion
of LT recipients who died that had grade ¾ HE was 60%
compared to 36% in those who survived.
Long-term clinical and functional outcomes
Assessment of long-term functional outcomes are
reported in Table 4 from the 353 patients who provided
follow-up data in person or via telephone interview
including 123 APAP initial survivors, 85 non-APAP ini-
tial survivors and 145 LT recipients. The rate of employ-
ment, marriage and having private insurance was lowest
in the APAP patients compared to others. In the sub-
group of patients with an available Karnofsky score, the
median score among the APAP initial survivors was
lower than the other two groups but this difference was
not statistically significant.
Medical and psychiatric comorbidities during long-term
follow-up
The frequency of diabetes, hypertension and hyperlip-
idaemia in the three groups were similar at the last avail-
able long-term follow-up study visit (Table 4).
However, ongoing psychiatric illness was significantly
more common in the APAP SS patients compared to
the other groups. Furthermore, problematic alcohol
consumption was significantly more commonly
reported in the APAP group compared to the others
and intentional drug overdose/suicide was also signifi-
cantly more common in the APAP SS patients.
Liver disease and laboratory status
The median values of serum AST, ALT, alk phos and
bilirubin were normal at the last available follow-up
visit in the three subgroups of patients. However, the
median serum total bilirubin levels were significantly
lower in the LT recipients compared to the other
patient groups while the median serum creatinine
levels were significantly higher in the LT recipients
(Table 4).
Discussion
ALF is a rare but potentially devastating illness that fre-
quently afflicts previously healthy and young individu-
als. The ALFSG and other groups have previously
reported that 3-week transplant-free survival is signifi-
cantly higher in subjects with APAP overdose, hepatitis
A, and pregnancy-related ALF (~60 to 70%) compared
to subjects with DILI, Wilson’s disease and indetermi-
nate ALF (~20 to 40%) (1–4). In addition, the ALFSG
demonstrated that patient age, initial and peak grade of
hepatic encephalopathy, and selected laboratory vari-
ables are associated with a greater likelihood of death
during the initial ALF hospitalization (1, 2). Currently,
Table 3. Univariate and multivariate models of 2-year survival in the three ALF patient groups
Univariate odds ratio (95% CI)* P-value Multivariate odds ratio (95% CI)* P-value
APAP initial spontaneous survivors C-Statistic: 0.647 (0.539, 0.755)
Age (per 10 years) 1.34 (1.02, 1.76) 0.038 1.27 (0.95, 1.71) 0.110
ALT (per 50 IU/L) 0.994 (0.987, 1.001) 0.071 – –
Phosphate (mg/dl) 1.28 (1.07, 1.54) 0.007 1.26 (1.05, 1.51) 0.015
Arterial pH 0.04 (0.001, 1.125) 0.059 – –
Initial HE (%3/4) 2.02 (0.96, 4.26) 0.064 – –
Pressor use 2.73 (1.07, 6.95) 0.035 – –
Dialysis/CVVH use 1.87 (0.84, 4.18) 0.128 – –
Non-APAP initial spontaneous survivors C-Statistic: 0.687 (0.596, 0.778)
Age (per 10 years) 1.44 (1.15, 1.80) 0.001 1.54 (1.17, 2.02) 0.002
Ethnicity (% Hisp/Lat) 0.36 (0.08, 1.62) 0.183 – –
Education (% <12 years) 2.16 (0.76, 6.10) 0.148 – –
Days from jaundice to ALF 1.03 (1.01, 1.06) 0.015 1.03 (1.00, 1.06) 0.028
ALT (per 50 IU/L) 0.987 (0.978, 0.997) 0.013 – –
INR 0.83 (0.64, 1.06) 0.138 – –
Pressor use 1.77 (0.76, 4.14) 0.185 – –
Liver transplant recipients C-Statistic: 0.741 (0.613, 0.869)
Age (10 years) 1.43 (1.02, 2.01) 0.036 1.53 (1.06, 2.21) 0.024
Days from jaundice to ALF 0.97 (0.93, 1.01) 0.113 0.97 (0.93, 1.01) 0.162
Days from symptoms to ALF 0.98 (0.95, 1.01) 0.18 – –
Initial HE (%3/4) 2.70 (1.06, 6.87) 0.037 2.57 (0.94, 7.05) 0.066
INR 0.78 (0.58, 1.05) 0.104 – –
MELD 0.96 (0.90, 1.02) 0.173 – –
Intubation use 2.28 (0.91, 5.73) 0.078 – –
Dialysis/CVVH use 2.31 (0.87, 6.14) 0.092 – –
*Odds are modelled as the probability of death.
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Table 4. Functional status at last follow-up visit among ALF long-term survivors
N*
APAP
initial
survivors
(N = 123)
Non-APAP
initial
survivors
(N = 85)
LT recipients
(N = 145) P-value
Demographics
Time of form collection (days) 276 704 ± 435 732 ± 424 746 ± 400 0.191
Age (years) 353 37.5 ± 12.8 42.2 ± 13.9 39.2 ± 13.0 0.044
% Female 353 95 (77.2) 53 (62.4) 95 (65.5) 0.040
Marital status
% Married 247 24 (30.8) 33 (54.1) 56 (51.9)
% Never married 247 34 (43.6) 19 (31.1) 30 (27.8) 0.025
% Other 247 20 (25.6) 9 (14.8) 22 (20.4)
Employment
% Employed 276 27 (29.0) 30 (45.5) 53 (45.3) <0.001
% Other 276 35 (37.6) 26 (39.4) 52 (44.4)
% Unknown 276 31 (33.3) 10 (15.2) 12 (10.3)
Years of education 197 11.8 ± 2.3 12.7 ± 2.3 12.6 ± 3.2 0.181
% Uninsured 276 14 (15.1) 5 (7.6) 2 (1.7) 0.001
% Private insurance 276 36 (38.7) 45 (68.2) 73 (62.4) <0.001
% Medicare 276 16 (17.2) 9 (13.6) 17 (14.5) 0.796
% Medicaid 276 12 (12.9) 5 (7.6) 18 (15.4) 0.312
Karnofsky score 197 86 ± 16 90 ± 12 90 ± 11 0.148
Substance abuse at last follow-up visit
Time of form collection (days) 344 762 ± 408 734 ± 443 746 ± 346 0.38
% Suicide attempt
No 325 80 (72.7) 59 (76.6) 124 (89.9) 0.004
Yes 325 7 (6.4) 2 (2.6) 3 (2.2)
Unknown 325 23 (20.9) 16 (20.8) 11 (8.0)
% Psychiatric disease
No 326 40 (36.0) 48 (62.3) 96 (69.6) <0.001
Yes 326 45 (40.5) 14 (18.2) 31 (22.5)
Unknown 326 26 (23.4) 15 (19.5) 11 (8.0)
% Alcohol abuse
No 325 71 (64.0) 55 (72.4) 126 (91.3) <0.001
Yes 325 14 (12.6) 4 (5.3) 1 (0.7)
Unknown 325 26 (23.4) 17 (22.4) 11 (8.0)
Medical complications at last follow-up visit
Time of form collection (days) 353 763 ± 375 738 ± 444 746 ± 370 0.601
% Neurological complications 353 33 (39.3) 16 (26.7) 42 (32.6) 0.276
% Diabetes mellitus 270 8 (9.8) 8 (13.3) 22 (17.2) 0.314
% Hypertension 256 15 (18.8) 13 (22.0) 27 (23.1) 0.763
% Hyperlipidaemia 267 9 (11.4) 7 (11.7) 9 (7.0) 0.454
Most recent labs
Time of last Lab (days) 320 224 ± 672 264 ± 695 709 ± 449 <0.001
Median AST (IU/L) 286 27 ± 46 30 ± 34 31 ± 27 0.669
% AST > ULN 286 41 (45.6) 26 (42.6) 69 (51.1) 0.491
Median ALT (IU/L) 287 39 ± 99 28 ± 44 31 ± 33 0.613
% ALT > ULN 287 47 (52.2) 26 (41.9) 58 (43.0) 0.316
Median alk phos (IU/L) 226 82 ± 33 82 ± 69 89 ± 78 0.336
% Alk phos > ULN 226 13 (20.3) 14 (31.1) 33 (28.2) 0.383
Median T. bilirubin (mg/dl) 284 0.7 ± 1.3 0.8 ± 2.0 0.6 ± 0.4 0.015
% Bilirubin > ULN 284 30 (33.7) 24 (40.0) 22 (16.3) <0.001
Median creatinine (mg/dl) 295 0.8 ± 0.6 0.9 ± 0.5 1.1 ± 0.5 <0.001
% Creatinine > ULN 295 20 (21.3) 9 (14.3) 39 (28.3) 0.082
Median haemoglobin (g/dl) 291 12.1 ± 2.8 12.9 ± 3.2 12.7 ± 2.1 0.033
% Haemoglobin < LLN 291 73 (76.8) 38 (64.4) 96 (70.1) 0.237
Median platelet count (9103/ml) 293 248 ± 140 210 ± 137 212 ± 89 0.011
% Platelet count < LLN 293 13 (13.8) 14 (23.0) 22 (15.9) 0.313
*Patient population defined by collection of outcome data at in person or via phone with chart review.
The following ULN values were used: AST ULN 30 IU/L, ALT ULN 35 IU/L, alk phos ULN 130 IU/L, bilirubin ULN 1.2 mg/dl, creatinine ULN 1.3 mg/dl.
The following LLN were used: Haemoglobin LLN 13.5 g/dl, platelet count LLN 150.
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many clinicians use these parameters and other labora-
tory and clinical features at the bedside to help guide
decisions regarding the need to list and proceed with LT
(3, 4). However, the long-term clinical outcomes in ALF
patients who survive their initial illness are not well
described. Understanding long-term outcomes in initial
survivors with ALF has proven difficult because of the
low incidence of the disease in the general population
with only 2000–3000 annual cases in the USA.
In this study, we were able to determine the 2-year
clinical outcomes in 773 ALF patients who had survived
their initial illness. The patients included in this analysis
are generally representative of the entire ALFSG cohort,
although fewer APAP patients were included compared
to the overall cohort (Table S1). Liver transplantation
yielded the highest 2-year survival at 92.4% compared
to the other two groups of initial spontaneous survivors.
These results are somewhat surprising as subjects who
require an emergency LT tend to be sicker at presenta-
tion compared to subjects that spontaneously recover
and would be expected to continue to have a substantial
risk of death during prolonged follow-up. The greater
initial severity of illness at presentation among the LT
recipients is supported by the higher initial and peak
serum bilirubin, INR, lactate and MELD scores in these
patients compared to the other two groups (Table 1).
The 20 deaths in the LT recipients occurred throughout
the 2 years of follow-up, while most of the deaths in the
initial spontaneous survivors tended to occur within
6 months of enrolment into the ALFSG study, suggest-
ing that ongoing hepatic damage may lead to fatal out-
comes after the initial illness. In attempting to
understand the reasons for the absolute differences in
mortality and time to death, we first looked at the causes
of death in the three patient groups. There was no
apparent differences in the stated causes of death but
there were moderate number of ‘unknown’ causes in
each subgroup (Table 2). A recent study of hospitalized
adult patients with APAP overdose in Canada demon-
strated that many of the patients died during 5 years of
follow-up from a variety of preventable causes including
trauma, substance abuse and other high-risk behaviours
(13). In addition, the survival of the APAP overdose
patients was significantly lower than the expected rate in
age-matched population controls. Therefore, the obser-
vation that roughly 10% of our APAP initial survivors
died during 2 years of follow-up is not entirely surpris-
ing. Our data also suggest that the increased frequency
of medical and psychiatric comorbidities in these high-
risk patients may require additional treatments and
interventions to improve long-term outcomes.
To further explore the observed differences in mortal-
ity, models of 2-year patient mortality were constructed
using baseline variables in all three patient subgroups
(Table 3). Of note, a higher patient age at admission was
significantly associated with impaired survival in both
the LT and non-APAP initial survivor groups. These
data are consistent with results of prior studies of LT
recipients which have also demonstrated that increased
patient age is a strong negative predictor of survival in
ALF patients (14–16). Other studies have also demon-
strated that liver regeneration is impaired in older livers
(14, 17). Therefore, our data are consistent with prior
studies demonstrating the importance of subject age in
surviving severe acute liver injury. In each of the sub-
groups, specific baseline features were identified as being
associated with impaired survival on multivariate analy-
sis (Table 3). Among the APAP patients, a higher phos-
phate level was associated with poorer survival which is
consistent with prior studies demonstrating that hyper-
phosphataemia is associated with poorer short-term
outcomes (18, 19). This association may be because of
impaired utilization of phosphate in liver regeneration
or simply as a marker of patients with poorer renal func-
tion. Unfortunately, serial serum phosphate levels during
the ALF hospitalization or during long-term follow-up
were not available for testing. In addition, a lower arterial
pH and higher arterial lactate levels are important pre-
dictors of short-term outcomes in the King’s college cri-
teria and arterial pH and INR were significant but only
on univariate analysis in our cohort (3, 4). However, we
did not detect a poorer long-term survival in APAP
patients with more advanced encephalopathy at presen-
tation. Nonetheless, other studies have demonstrated
that severe cerebral oedema is predictive of poor neuro-
logical outcomes and survival in ALF patients (20, 21).
Among the non-APAP initial survivors, age, serum
ALT levels, and a longer duration of symptoms were all
identified on univariate analyses as associated with a
lower likelihood of long-term survival (3, 21–24). The
ALFSG has previously shown that Hispanic patients are
more likely to have a lower transplant-free survival rate
compared to non-Hispanic patients in part because of
their greater likelihood of having DILI (25). However in
multivariate analysis, only patient age and a longer
duration of symptoms to ALF onset were significant and
independent predictors of death. A poorer outcome in
patients with subacute ALF that present with more
slowly but inevitably progressive liver injury than those
with hyperacute ALF has been previously reported (26,
27). Furthermore, the majority of these non-APAP
patients were never listed for LT and nearly 20% had
ALF because of ischaemic hepatitis which is associated
with severe underlying cardiopulmonary disease that
frequently precludes LT (10).
Among the LT recipients, patient age and more
advanced encephalopathy at presentation were associ-
ated with poorer 2-year survival on univariate analyses.
These data are consistent with prior studies that demon-
strate the critical importance of the initial and peak
encephalopathy grade in predicting outcome in ALF (3,
28, 29). However, in multivariate analysis only age and
the days from jaundice to ALF onset remained indepen-
dent predictors of outcomes. Although other studies
have demonstrated that LT recipients with APAP over-
dose are at increased risk of graft failure compared to
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other ALF patients, we were not able to identify a
relationship between the aetiology of ALF and death
during prolonged follow-up possibly because of the lim-
ited number of deaths in this population.
A careful review of the functional outcomes in the
three patient groups demonstrated some important and
interesting differences (Table 4). For example, LT recipi-
ents were significantly more likely to be employed com-
pared to the other two groups both at presentation and
during follow-up. These observations may in part be
because of the lower socioeconomic status of patients
who present with APAP overdose compared to the other
two groups. Although nearly 40% of the APAP overdose
patients were non-intentional ‘therapeutic misadven-
tures’ who received toxic doses of multiple APAP prod-
ucts there was a significantly higher rate of concomitant
substance abuse and psychiatric disease requiring treat-
ment in the APAP SS group during follow-up compared
to the other two groups which was independent of inten-
tionality (29). In addition, 6.1% of the APAP initial sur-
vivors reported another episode of drug overdose/suicide
which is also consistent with prior studies of repeated
high-risk behaviours in this patient population (13).
Recent studies have demonstrated that LT recipients
with ALF have a lower rate of employment compared to
cirrhotic LT recipients despite their younger age (30). In
addition, ALF patients experience higher rates of depres-
sion, anxiety, and post-traumatic stress disorder after
liver transplantation compared to cirrhotic LT recipi-
ents (31). Whether this is because of the sudden onset
of a severe life-threatening illness in generally young
and previously well ALF patients compared to chroni-
cally ill cirrhotic LT recipients is not known but plausi-
ble. The Karnofsky scores which are indicative of global
health status tended to be higher in the LT recipients
compared to the other two groups although the differ-
ence did not reach statistical significance. In a recent
analysis of health related quality of life measures in a
subgroup of ALFSG long-term survivors, we showed
that the LT recipients had significantly higher SF-36 and
CDC-14 scores during follow-up compared to the APAP
and non-APAP initial survivors (32). These cumulative
data suggest that both APAP and non-APAP initial sur-
vivors appear to have poorer general physical and men-
tal health compared to the LT recipients during long-
term follow-up in addition to a lower overall survival.
As such, a significant subset of ALF spontaneous survi-
vors may benefit from targeted interventions including
counselling, psychiatric care, and physical therapy to
achieve improved long-term health outcomes.
The median serum AST, ALT, alk phos, and bilirubin
levels were normal in all of the patients in each of the
three patient subgroups during their most recent fol-
low-up visit (Table 4). The significantly lower total bili-
rubin levels in the LT recipients is somewhat surprising
and suggests that the APAP and non-APAP initial survi-
vors may have poorer bilirubin clearance. However, our
study was not designed to assess liver disease status via
histological sampling or radiological imaging to further
explore this observation. We surmise that the higher
mean serum creatinine levels in the LT recipients likely
relates to the use of nephrotoxic calcineurin inhibitors
to prevent rejection. However, only 28% of the LT
recipients had an elevated serum creatinine level so the
degree of renal insufficiency appears to be mild. In addi-
tion, the incidence of diabetes and hypertension was
generally low and similar in the three patient groups.
Limitations of this study include the incomplete fol-
low-up of all 1172 eligible ALF survivors at 3 weeks
(Fig. 1). One of the reasons for incomplete follow-up is
that over 80% of the ALF patients are transferred to an
ALFSG site for tertiary liver care. For patients that sur-
vive their index hospitalization with no evidence of
residual liver injury, continued follow-up at a referral
centre that may be several hours from their home, can
be challenging. This may in part explain the larger pro-
portion of APAP initial survivors who did not return
for follow-up (Table S1). In addition, continued partici-
pation in a non-interventional registry study would be
expected to have a lower rate of follow-up than a clinical
trial. Lastly, 45% of the ALF patients that died during
prolonged follow-up did not have an identifiable cause
of death (Table 2). This rate of incomplete data is simi-
lar to those seen in other population and cohort-based
studies of long-term outcomes of patients (33, 34). The
incomplete reporting of the causes of death in our study
may again relate to the absence of long-term medical
follow-up in the liver centre because of logistical issues
as well as our inability to routinely obtain Death Certifi-
cates or causes of death from the Social Security Death
Index. In addition, the declining use of autopsy in
patients that die in a hospital setting and the difficulty
to accurately ascertain the cause of death in individuals
without an autopsy may have played a role (33, 35, 36).
Despite these limitations, our study represents the larg-
est cohort of adult ALF patients that were prospectively
followed beyond 21 days and up to 2 years. In addition,
the severity of illness and other clinical features of the
enrolled patients were generally similar to the excluded
patients. Another limitation of this study was that we
did not account for donor, operative or immunosup-
pression variables when attempting to explore outcomes
in the LT recipients. This was because of the fact that
our study was not intended to standardize the treatment
or monitoring of ALF patients after LT. Furthermore,
the limited number of deaths in the LT recipients may
have precluded adequate power to identify other predic-
tors of long-term outcomes.
In conclusion, our study results demonstrate that
the 2-year clinical outcomes in early survivors with
ALF are generally very good. Although nearly 40% of
initial adult ALF patients die during their index hospi-
talization, the mortality rate among initial 3-week
survivors is substantially lower during more prolonged
follow-up. Contrary to our initial hypothesis, the non-
APAP initial survivors have a significantly lower 2-year
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survival compared to the LT recipients and APAP ini-
tial survivors. Most of the deaths in the initial sponta-
neous survivors occurred within the first 6 months of
observation because of a multitude of causes suggest-
ing that early careful follow-up after an ALF episode
is warranted. Among the long-term survivors, the
APAP initial survivors had the lowest rates of employ-
ment which may be because of their lower baseline
socioeconomic status and more frequent medical and
psychiatric comorbidities compared to the other
patient groups. Laboratory markers of liver injury
demonstrated normal or near normal parameters in
most patients during follow-up. Therefore, despite the
need for intubation, dialysis and pressors in many
ALF patients during their acute illness, most will
recover with intact liver function during follow-up.
Although mortality is highest in the non-APAP initial
survivors, the overall favourable 2-year survival can
help guide future studies of additional interventions to
improve clinical outcomes in these patients.
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